Outlook Therapeutics Inc (NASDAQ: OTLK) reported its financial results for the third quarter of fiscal year 2026, ended June 30, 2026, on August 14. The Iselin, New Jersey-based biopharmaceutical company posted a GAAP net loss attributable to common stockholders of $20.3 million, or $0.15 per basic and diluted share. This represents a substantial improvement from the $20.2 million, or $0.55 per share, net loss recorded in the same period last year.

On a non-GAAP basis, the company reported an adjusted net loss of $10.9 million, or $0.09 per basic and diluted share, compared to an adjusted net loss of $15.8 million, or $0.44 per share, in Q3 FY25. The improvement in both GAAP and adjusted metrics reflects effective cost management, although top-line activity contracted sharply.

Financial Performance

Revenue for the quarter fell dramatically to $9,000, down from $1.5 million reported in the year-ago period. This decline indicates a significant reduction in milestone recognitions or commercial activities compared to the prior year. Cost of revenues also decreased to $17,000 from $440,000 in Q3 FY25.

Operating expenses showed notable reductions:

• Research and development expenses fell to $3.3 million from $7.1 million in the prior year period.
• Selling, general and administrative expenses declined to $7.6 million from $9.7 million.

The GAAP net loss included several non-cash items that were excluded from the adjusted metric. These adjustments included a $7.0 million loss from the change in fair value of warrant liability, a $1.3 million loss on extinguishment of debt, and a $1.1 million loss from the change in fair value of promissory notes. In contrast, the prior year period included a $2.0 million loss from warrant liability changes and a $2.3 million loss from promissory note fair value changes.

Note: Figures rounded to one decimal place where applicable. N/M denotes not meaningful due to sign change.

Capital Raise and Liquidity

Subsequent to the quarter end, in August 2026, Outlook Therapeutics announced a public offering of 55,555,556 shares of common stock and accompanying warrants. The combined public offering price was $0.99 per share and warrant, generating approximately $51.1 million in net proceeds after deducting underwriting discounts and commissions.

As of June 30, 2026, the company held cash and cash equivalents of $11.2 million. This balance did not include the proceeds from the August offering. Total assets stood at $26.2 million, while current liabilities were $28.7 million. Total stockholders’ deficit improved to $(10.4 million) from $(32.2 million) at the end of the previous fiscal year.

Business Update: LYTENAVA Launch Preparations

Outlook Therapeutics continues to advance preparations for the U.S. commercial launch of LYTENAVA (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The company plans to launch in the United States by the end of calendar 2026.

Management believes LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030. Key launch activities include:

• Expanding payer engagement and scaling commercial supply.
• Building a focused commercial organization with deep retina expertise.
• Submitting an application for a permanent Healthcare Common Procedure Coding System (HCPCS) code by October 1, 2026, to support reimbursement.

In Europe, the company is expanding commercialization in Germany, Austria, and the United Kingdom. A planned launch in the Netherlands is expected later in 2026 following regulatory submission. In Switzerland, partner Mediconsult is leading activities toward an anticipated 2027 launch.

What the Numbers Show

The divergence between the narrowing adjusted net loss and the near-total collapse in revenue highlights a strategic shift toward cost containment ahead of commercialization. While R&D expenses fell more than 50%, SG&A expenses remained elevated at $7.6 million, suggesting ongoing investment in pre-launch infrastructure. The $51.1 million capital raise provides critical liquidity, increasing available cash from $11.2 million to approximately $62.3 million, which should support the planned U.S. launch through 2026 without immediate need for further dilution.

Analyst Ratings

Wall Street analysts have issued varied ratings for Outlook Therapeutics in recent months. Below are the most recent actions from analysts with high accuracy rates:

BTIG analyst Julian Harrison upgraded the stock from Neutral to Buy with a price target of $4 on July 27, 2026. In contrast, Guggenheim analyst Eddie Hickman downgraded the stock from Buy to Neutral on August 29, 2025. HC Wainwright & Co. analyst Douglas Tsao maintained a Neutral rating but raised the price target from $0.5 to $1.6 on July 27, 2026.

Outlook Therapeutics Inc (NASDAQ: OTLK) has priced an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to 55,555,556 shares. The biopharmaceutical company, focused on the development and commercialization of LYTENAVA (bevacizumab-vikg) for retinal diseases, aims to fund the US commercial launch of its lead asset through this capital raise.

The combined public offering price for each share of common stock and accompanying warrant is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisable immediately, and will expire five years from the date of issuance. The aggregate gross proceeds to Outlook Therapeutics from the offering are expected to be approximately $55.0 million, before deducting underwriting discounts and commissions and offering expenses.

Offering Details

Piper Sandler and BTIG are acting as joint bookrunning managers for the transaction, while Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as lead manager. All securities in the proposed offering are to be sold directly by Outlook Therapeutics.

Outlook Therapeutics granted the underwriters an option for a period of 30 days to purchase up to 8,333,333 additional shares of its common stock and/or warrants to purchase up to 8,333,333 additional shares at the public offering price, less underwriting discounts and commissions.

Use of Proceeds

The company stated it intends to use the net proceeds from the offering, together with existing cash and cash equivalents, for two primary purposes:

• Supporting the commercial launch of LYTENAVA in the United States.
• Working capital and general corporate purposes.

The offering is being made pursuant to a "shelf" registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission on March 28, 2024, and declared effective on April 5, 2024. The offering remains subject to completion based on prevailing market conditions and customary closing conditions.